The Effects of Probiotic Honey Consumption on Metabolic Status in Patients with Diabetic Nephropathy: a Randomized, Double-Blind, Controlled Trial (Publication with Expression of Concern)
The Effects of Probiotic Honey Consumption on Metabolic Status in Patients with Diabetic Nephropathy: a Randomized, Double-Blind, Controlled Trial (Publication with Expression of Concern)
复制标题
DOI：
10.1007/s12602-018-9468-x
复制
发表时间：
2019-12-01
影响因子：
4.9
通讯作者：
Asemi, Zatollah
中科院分区：
文献类型：
--
作者：
Arani, Navid Mazruei;Emam-Djomeh, Zahra;Asemi, Zatollah
据我们所知，这项研究是第一次评估益生菌蜂蜜摄入对糖尿病肾病（DN）患者血糖控制、脂质谱、炎症生物标志物和氧化应激的影响。本研究旨在评估益生菌蜂蜜摄入对DN患者代谢状况的影响。这项随机、双盲、对照的临床试验在60例DN患者中进行。患者被随机分为两组，接受25 g/天的益生菌蜂蜜，其中含有活菌和耐热益生菌凝结芽孢杆菌T11 (IBRC-M10791) （10(8) CFU/g）或25 g/天的对照蜂蜜（每组30例），为期12周。在基线和补充后12周采集空腹血液样本，以量化血糖状态、脂质浓度、炎症生物标志物和氧化应激。干预12周后，与对照组相比，服用益生菌蜂蜜的患者血清胰岛素水平显著降低（- 1.2 +/- 1.8 vs - 0.1 +/- 1.3 mu IU/mL, P = 0.004），胰岛素抵抗稳态评估模型显著降低（- 0.5 +/- 0.6 vs. 0.003 +/- 0.4, P = 0.002），胰岛素敏感性定量检查指数显著改善（+ 0.005 +/- 0.009 vs. - 0.0007 +/- 0.005, P = 0.004）。此外，与对照蜂蜜相比，摄入益生菌蜂蜜导致总胆固醇/高密度脂蛋白胆固醇显著降低（- 0.2 +/- 0.5 vs. + 0.1 +/- 0.1, P = 0.04）。与对照蜂蜜相比，摄入益生菌蜂蜜显著降低血清高敏c -反应蛋白（hs-CRP） （- 1.9 +/- 2.4 vs - 0.2 +/- 2.7 mg/L, P = 0.01）和血浆丙二醛（MDA）水平（- 0.1 +/- 0.6 vs. + 0.6 +/- 1.0 mu mol/L, P = 0.002）。与对照蜂蜜相比，摄入益生菌蜂蜜对其他代谢特征没有显著影响。总的来说，目前的研究结果表明，在DN患者中食用益生菌蜂蜜12周对胰岛素代谢、总胆固醇/高密度脂蛋白胆固醇、血清hs-CRP和血浆MDA水平有有益的影响，但对其他代谢特征没有影响。: IRCT201705035623N115。
To the best of our knowledge, this study is the first evaluating the effects of probiotic honey intake on glycemic control, lipid profiles, biomarkers of inflammation, and oxidative stress in patients with diabetic nephropathy (DN). This investigation was conducted to evaluate the effects of probiotic honey intake on metabolic status in patients with DN. This randomized, double-blind, controlled clinical trial was performed among 60 patients with DN. Patients were randomly allocated into two groups to receive either 25 g/day probiotic honey containing a viable and heat-resistant probiotic Bacillus coagulans T11 (IBRC-M10791) (10(8) CFU/g) or 25 g/day control honey (n = 30 each group) for 12 weeks. Fasting blood samples were taken at baseline and 12 weeks after supplementation to quantify glycemic status, lipid concentrations, biomarkers of inflammation, and oxidative stress. After 12 weeks of intervention, patients who received probiotic honey compared with the control honey had significantly decreased serum insulin levels (- 1.2 +/- 1.8 vs. - 0.1 +/- 1.3 mu IU/mL, P = 0.004) and homeostasis model of assessment-estimated insulin resistance (- 0.5 +/- 0.6 vs. 0.003 +/- 0.4, P = 0.002) and significantly improved quantitative insulin sensitivity check index (+ 0.005 +/- 0.009 vs. - 0.0007 +/- 0.005, P = 0.004). Additionally, compared with the control honey, probiotic honey intake has resulted in a significant reduction in total-/HDL-cholesterol (- 0.2 +/- 0.5 vs. + 0.1 +/- 0.1, P = 0.04). Probiotic honey intake significantly reduced serum high-sensitivity C-reactive protein (hs-CRP) (- 1.9 +/- 2.4 vs. - 0.2 +/- 2.7 mg/L, P = 0.01) and plasma malondialdehyde (MDA) levels (- 0.1 +/- 0.6 vs. + 0.6 +/- 1.0 mu mol/L, P = 0.002) compared with the control honey. Probiotic honey intake had no significant effects on other metabolic profiles compared with the control honey. Overall, findings from the current study demonstrated that probiotic honey consumption for 12 weeks among DN patients had beneficial effects on insulin metabolism, total-/HDL-cholesterol, serum hs-CRP, and plasma MDA levels, but did not affect other metabolic profiles. : IRCT201705035623N115.